Author's response to reviews

Title: Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection

Authors:

Daniel Bremell (daniel.bremell@infect.gu.se)
Niklas Mattsson (niklas.mattsson@neuro.gu.se)
Mikael Edsbagge (mikael.edsbagge@neuro.gu.se)
Kaj Blennow (kaj.blennow@neuro.gu.se)
Ulf Andreasson (ulf.andreasson@neuro.gu.se)
Carsten Wikkelsö (ulf.andreasson@neuro.gu.se)
Henrik Zetterberg (henrik.zetterberg@clinchem.gu.se)
Lars Hagberg (henrik.zetterberg@clinchem.gu.se)

Version: 2 Date: 25 May 2012

Author's response to reviews: see over
Cover letter

Dear Sir/Madame

We have now uploaded a version of the article revised according to your recommendations.

1. The Methods section now includes a consent statement. According to Swedish regulations, the patient has to give his/her consent prior to the inclusion of a sample into a biobank. For the samples of that biobank to be used in a specific study, the Regional Ethical Review Board decides whether each sampled patient has to be individually informed or not.

2. All authors’ individual e-mail addresses are now included in the submission system.

3. The Methods section includes a reference to the guidelines published by the Swedish Medical Products Agency (“Läkemedelsverket”) for the treatment of Borrelia infections.

We hope that having made these revisions, the article can now be sent for peer-review.

Sincerely,

Daniel Bremell
Niklas Mattsson
Mikael Edsbagge
Kaj Blennow
Ulf Andreasson
Carsten Wikkelso
Henrik Zetterberg
Lars Hagberg